Geron swings to Q3 2026 net profit of $1.35 million from year-earlier loss

• Geron swung to third-quarter 2026 net income of $1.35 million from a year-earlier net loss of $18.43 million.
• Product revenue, net rose 27% year over year to $60.11 million, while total costs and operating expenses fell 11% to $54.39 million.
• The Phase 3 IMpactMF trial was discontinued following an independent committee’s assessment that it was unlikely to meet its overall-survival endpoint.
• A targeted European RYTELO launch began, with availability expected in Germany by year-end and France in 2027.
• FY26 product revenue, net guidance remained at $220 million–$240 million’s mid-to-high end; operating expense guidance fell to $220 million–$230 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040703PRIMZONEFULLFEED9870031) on November 04, 2026, and is solely responsible for the information contained therein.